Speclipse, Covera Health, Elixiron Immunotherapeutics
Cardiomatics bags $3.2M for its ECG-reading AI
Poland-based health tech AI startup Cardiomatics has announced a $3.2 million seed raise to expand use of its electrocardiogram (ECG) reading automation technology.
The round is led by Central and Eastern European VC Kaya, with Nina Capital, Nova Capital and Innovation Nest also participating.
The seed raise also includes a $1 million non-equity grant from the Polish National Centre of Research and Development.
The 2017-founded startup sells a cloud tool to speed up diagnosis and drive efficiency for cardiologists, clinicians and other healthcare professionals to interpret ECGs — automating the detection and analysis of some 20 heart abnormalities and disorders with the software generating reports on scans in minutes, faster than a trained human specialist would be able to work.
Cardiomatics bags $3.2M for its ECG-reading AI | TechCrunch
Poland-based health tech AI startup Cardiomatics has announced a $3.2 million seed raise to expand use of its electrocardiogram (ECG) reading automation technology. The round is led by Central and Eastern European VC Kaya, with Nina Capital, Nova Capital and Innovation Nest also participating. The seed raise also includes a $1 million non-equity grant from […]
SolasCure Raises UK£1.2M in Funding
SolasCure, a Cambridge, UK-based biotech startup, raised £1.2m in funding.
Seneca Partners invested:
£733k invested via Seneca EIS Portfolio Service, and
£500K via Seneca Growth Capital VCT.
The company intends to use the funds for the further development of its wound cleaning product, Aurase®.
Led by Dr. Sam Bakri, Executive Chairman and CEO, SolasCure is developing proprietary technology leveraging biomimicry and evidence-based medicine to empower health care professionals to treat patients with chronic wounds. Its first investigational product, Aurase®, is a hydrogel containing an enzyme cloned from medical maggots that can be used to support healthcare professionals treating patients with chronic wounds.
SolasCure Raises UK£1.2M in Funding - FinSMEs
SolasCure, a Cambridge, UK-based biotech startup, raised £1.2m in funding from Seneca Partners
Speclipse Raises $7.7M in Funding
Speclipse, a Seoul, South Korea-based developer of laser spectroscopic and AI-based medical diagnosis technologies, raised $7.7M in funding.
The round was led by Signite Partners with participation from BNH Investment, Shinhan Capital, MiCo and MiCoBioMed.
The company intends to use the funds to accelerate growth, expand operations and its business reach.
Led by Sung Hyun Pyun, Speclipse provides a laser spectroscopic technique and artificial intelligence technology – originally used for tissue diagnostics – to blood analysis. The company’s laser spectroscopic technology overcomes the limitations of existing blood analysis technologies in that it can simultaneously detect small variances in various blood biomarkers. Speclipse also uses Al and deep learning technologies to process and analyze large amounts of blood spectroscopic data, thereby enabling the early diagnosis of gastric cancer and Alzheimer’s disease.
Speclipse Raises $7.7M in Funding
Speclipse, a Seoul. South Korea-based developer of laser spectroscopic and AI-based medical diagnosis technologies, raised $7.7M in funding
Covera Health Raises $25M in Series C Funding
Covera Health, a New York-based healthcare quality analytics company, raised $25M in Series C funding.
The round was led by Insight Partners with participation from Equity Group Investment.
The company intends to use the funds to accelerate the scaling of its CoE program, enhance the platform’s underlying medical error detection technology, deepen its data integrations across payers and providers, while continuing to grow and scale the organization.
Led by founder and CEO Ron Vianu, Covera Health is a quality analytics company focused on improving patient care by reducing medical errors like prevalence and impact of misdiagnoses, cause of inappropriate care, poor patient outcomes, and unnecessary medical expense. The platform leverages advanced data science and artificial intelligence to improve outcomes across a wide range of medical conditions and diseases, from musculoskeletal and spinal conditions to breast and lung cancers. Its national Radiology Centers of Excellence (CoE) program is used by some of the largest employers and health plans in the nation, serving millions of patients across the country.
https://www.finsmes.com/2021/08/covera-health-raises-25m-in-series-c-funding.html
Techcyte Closes $21M in Funding
Techcyte, a Orem UT-based based digital clinical pathology platform, raised $21M in funding.
The round was led by Zoetis with participation from ARUP Laboratories and investors from previous rounds.
The company intends to use the funds to grow its veterinary business and accelerate commercialization in the human market, completing multiple FDA 510ks and expanding the development team to further work with valued partners such as ARUP Laboratories.
Led by CEO Ben Cahoon and President Rick Smith, Techcyte provides a clinical pathology platform which uses AI-based workflows and integration with whole slide scanners and lab information systems to increase the accuracy and efficiency of clinics and labs. It is used for human, veterinary and environmental diagnostic testing.
Techcyte Closes $21M in Funding - FinSMEs
Techcyte, a Orem UT-based based digital clinical pathology platform, raised $21M in funding
Element5 Raises $15M in Series A Funding
Element5, a San Jose, Calif.-based Automation as a Service solution for post-acute care, closed a $15m Series A funding.
The round was led by Insight Partners with participation from Maxwell Investment Partners. As part of the deal, Insight Partners’ Jared Rosen is joining the board of directors at Element5.
The company, which has raised a total capital of $18.5m, will use the funding to accelerate growth of their product for post-acute care, while strengthening its market presence through customer expansion and scaling of global operations.
Founded in 2019 and led by Joe Randesi, CEO, Element5 uses Artificial Intelligence (AI) and Robotic Process Automation (RPA) to deliver SaaS-based automated workflows for home-health, hospice, senior living, skilled nursing and other allied healthcare verticals. It delivers end-to-end workflow automation that uses software robots, which log into everyday systems and perform daily administrative tasks like a human would, helping teams save hours on repetitive clicks. With its offering, organizations can deploy automated workflows across patient intake, authorizations, medical records, revenue cycle management and analytics.
Element5 Raises $15M in Series A Funding
Element5, a San Jose, Calif.-based Automation as a Service solution for post-acute care, closed a $15m Series A funding
Elixiron Immunotherapeutics Closes $27M Series A-1 Financing Round
Elixiron Immunotherapeutics, Inc., a company developing therapeutics for cancer, neurological diseases and inflammatory disorders, closed a $27m Series A-1 extension financing round, bringing the total Series A-1 raise to $27m.
The round was jointly led by Pangu Capital (a new investor) and Taiwania Capital (an existing investor) and was joined by further new investors, including DCI Partners of Daiwa Securities Group, Mega International Commercial Bank, Fubon Financial Holdings and Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.
Founded in 2017 and led by Hung-Kai Chen, Founder, CEO and Chairman of the Board, Elixiron is a biotechnology company with operations in San Francisco, Taipei and Shanghai on a mission to develop next-generation immunotherapies for neurodegenerative and immunological disorders, as well as cancer, by tapping into what human clinical findings can teach us for reverse-translational medicine approaches.
The company intends to use the funds to advance phase 1 trials of two pipeline candidates and take three immuno-oncology assets towards IND applications.
EI-1071 is an orally available, highly potent Colony-Stimulating Factor 1 Receptor inhibitor that is in a phase 1 trial in part thanks to an Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program award.
EI-001 is a fully human antibody that neutralizes an immuno-modulatory target of interest in Vitiligo and some other immunological disorders including Chronic Hepatitis B.
https://www.finsmes.com/2021/08/elixiron-immunotherapeutics-closes-27m-series-a-1-financing-round.html
Circles Raises $8M in Seed Funding
Circles, a Tel Aviv, Israel-based emotional support platform, raised $8m in seed funding.
The round was led by NFX and Flint Capital with participation from Sir Ronald Cohen, Jeff Swartz and others.
Circles was founded in 2020 by Irad Eichler and Dan Landa, Circles leverages proprietary technology and the expertise of a leadership team that specializes in mental wellbeing to enable meaningful connections and establish supportive communities that are led by professional facilitators and built on mutual care. The platform matches groups of 6-8 people who are facing similar issues in their lives (such as grief, relationships and separation or divorce) in intimate and private emotional support sessions where they can be understood.
Circles Raises $8M in Seed Funding
Circles, a Tel Aviv, Israel-based emotional support platform, raised $8m in seed funding led by NFX and Flint Capital
Maven Clinic Raises $110M in Series D Funding
Maven Clinic, a New York-based virtual clinic company, raised $110M in Series D funding.
The round, which brought total funding to more than $200m, was led by Dragoneer Investment Group, Lux Capital with participation from BOND, Sequoia, Oak HC/FT, and Icon Ventures, as well as Oprah Winfrey. In conjunction with the funding, Eric Jones, partner at Dragoneer Investment Group, is joining Maven’s Board of Directors along with Deena Shakir, partner at Lux Capital.
The company intends to use the funds to expand into new populations and to invest in additional product innovation to further enhance its member experience designed to improve clinical outcomes.
Founded in 2014 by CEO Kate Ryder, Maven Clinic provides virtual clinic for women’s and family health, offering continuous, holistic care for fertility, pregnancy and parenting. Maven’s platform combines an expansive, specialized telehealth network of more than 30 provider types with individual care navigation to support all parents and all paths to parenthood, from fertility through pregnancy, parenting and pediatrics.
Maven Clinic Raises $110M in Series D Funding
Maven Clinic, a New York-based virtual clinic company, raised $110M in Series D funding
Immunitas Therapeutics Closes $58M in Series B Financing
Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP).
The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.
Led by Jeffrey Goldberg, Chief Executive Officer, Immunitas Therapeutics is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple programs to the clinic. Its programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator.
Immunitas Therapeutics Closes $58M in Series B Financing - FinSMEs
Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing
Jnana Therapeutics Closes $50M Series B Financing
Jnana Therapeutics, a Boston, Mass.-based biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, closed a $50m Series B financing.
The round was led by RA Capital Management, with participation from existing investors Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures. In conjunction with the funding, Matthew Hammond, Ph.D., Principal at RA Capital, will join Jnana’s Board of Directors.
The company intends to use the funds to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.
Led by Joanne Kotz, Ph.D., Co-founder, Chief Executive Officer and President, Jnana Therapeutics is a biotechnology company utilizing a next generation chemoproteomic platform to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters. Jnana is focused on developing therapies to treat a wide range of diseases, including immune-mediated, neurological and metabolite-dependent diseases.
Jnana Therapeutics Closes $50M Series B Financing - FinSMEs
Jnana Therapeutics, a Boston, Mass.-based biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, closed a $50m Series B financing
ClosedLoop.ai Raises $34M in Series B Funding
ClosedLoop.ai., an Austin, Texas-based healthcare’s data science platform, raised $34m in Series B financing.
The round was led by Telstra Ventures with participation from Breyer Capital, Greycroft Ventures, .406 Ventures, and Healthfirst, with participation from angel investors Adam Boehler (former director of CMMI & CEO of Rubicon Founders) and Sam Palmisano (former CEO of IBM).
The company intends to use the funds to continue to expand the reach its artificial intelligence (AI) solutions.
ClosedLoop.ai provides a healthcare’s data science platform that enables healthcare organizations to use AI to improve outcomes and reduce costs. The system combines an end-to-end machine learning platform with a comprehensive library of healthcare-specific features and model templates to allow customers to improve clinical results, operational efficiency, value-based contracts, and increase revenue.
https://www.finsmes.com/2021/08/closedloop-ai-raises-34m-in-series-b-funding.html
Ranok Therapeutics Raises $40M in Series B Financing
Ranok Therapeutics (Hangzhou) Co. Ltd., a Hangzhou, China-based biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, secured a $40m Series B funding round.
The round was led by Lapam Capital and Shanghai Healthcare Capital, with participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors. Representatives of the new investors will join Ranok’s expanded board of directors. To date, Ranok has raised the equivalent of over $50m in funding.
The company intends to use the funds to:
enable its first cancer therapeutic to progress into the clinic,
develop its proprietary CHAMP tumor-targeted protein degrader platform, and
expand its preclinical pipeline of novel therapies based on the CHAMP tech platform.
Led by Weiwen Ying, Ph.D., Founder and Chief Executive Officer, Ranok has developed a proprietary and innovative targeted protein degradation (TPD) platform technology, CHAMP (Chaperone-mediated Protein Degradation), that leverages its founders’ expertise in protein homeostasis to take advantage of the cellular chaperome network, potentially improving drug safety and efficacy due to selective targeting of disease tissues.
Ranok Therapeutics Raises $40M in Series B Financing - FinSMEs
Ranok Therapeutics (Hangzhou) Co. Ltd., a Hangzhou, China-based biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, secured a $40m Series B funding round
South African e-health startup VitruvianMD has raised an eight-figure ZAR – so at least ZAR10 million (US$659,000) – funding round in order to scale its tech and launch more pilots.
VitruvianMD’s eight-figure ZAR funding round was led by the Singapore-based Verge Healthtech Fund and also features a host of angel investors. It will be used to accelerate the development of the startup’s technology and to fund the roll-out of additional pilots.
With this funding, the goal is to reach commercialisation of at least one of our diagnostic modules within the next 18 months.
Founded last year, VitruvianMD combines biomedical engineering and state-of-the-art artificial intelligence (AI) to deliver affordable, high-accuracy diagnostic tools for medical laboratories, with a particular focus on servicing emerging markets.
https://disrupt-africa.com/2021/08/20/sa-e-health-vitruvianmd-raises-8-figure-zar-funding-round/